Thyroid cancer

Differentiated Thyroid Cancer
  - Adjuvant therapy
  - Advanced radioactive iodine refractory
    - No Studies Available

Medullary Thyroid Cancer
  - IRB #15341
    - A Multicenter, Randomized, Double-blind Phase 2 Trial of Lenvatinib in Subjects With 131I-Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 20 mg or 14 mg Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose

Anaplastic Thyroid Cancer
  - No Studies Available

Advanced Thyroid Cancer

CROSS-DISEASE TRIALS:
  - IRB# TBD
    - EAY131 (MATCH)
  - IRB# TBD
    - S1609 (DART)

IRB #20359
- A Multicenter, Randomized, Double-blind Phase 2 Trial Comparing LOXO-292 to Physicians Choice of Cabozantinib or Vandetanib in Patients with Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-331)